BUSINESS BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9 Wednesday, March 11, 2026 · bridgebio pharma, inc. Advertisement Read Original Article → Related Dispatches [US] · Jun 28 With the state’s last known elevator operator, Nicollet Mall office building honors its past [EU] · Jun 28 Bitcoin Defends $59K Support as Q2 Closes With Rare Back-to-Back Loss [EU] · Jun 28 Why Professional Audit and Advisory Services Are Essential for Business Growth